ロード中...
Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome
Rasburicase is a recombinant urate oxidase enzyme approved for use in tumor lysis syndrome (TLS) and it acts by reducing serum uric acid levels. Using rasburicase at the recommended dose of 0.2 mg/kg/day for 5 days is expensive and it is not known whether this extended schedule is clinically benefic...
保存先:
| 出版年: | Indian J Hematol Blood Transfus |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer India
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6186245/ https://ncbi.nlm.nih.gov/pubmed/30369730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12288-018-0938-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|